- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Episode 2 - Variability in Disease Course and Treatment Approach
Because each patient with castration-resistant prostate cancer (CRPC) experiences a different disease course, clinicians need to evaluate several factors when making treatment decisions, explains Christopher Sweeney, MBBS.
As an example, Dr Sweeney describes 2 patient cases and discusses the criteria he uses to determine whether to recommend hormonal therapy (eg, with agents such as abiraterone or enzalutamide) or nonhormonal therapy (ie, chemotherapy).
Based on the variability of disease course in patients with CRPC, research on tumor heterogeneity is being conducted. An area that is currently being investigated is a variation in the androgen receptor that allows tumor cells to grow despite testosterone blockade and androgen receptor blockade. Dr Sweeney remarks that this variation of the androgen receptor holds promise as a biomarker to help determine whether or not a patient would respond to hormonal therapy.
Watch our related Peer Exchange, Oncology Stakeholder Summit 2014: Evidence-Based Decisions to Improve Quality and Regulate Costs
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
